THCA Therapeutics has completed a controlled technical development package for THCA PURE™ Oral, our investigational oral formulation platform.

The package defines the current product architecture and outlines the analytical, manufacturing, GMP, CMC, stability, packaging, and decarboxylation-control requirements for evaluation by a qualified pharmaceutical development and manufacturing partner.

A confidentiality agreement has been executed with a prospective CDMO, enabling detailed technical feasibility assessment and preparation of a structured development and cost proposal.

Current workstreams include:

• CDMO feasibility and manufacturing assessment
• Analytical method and THCA integrity planning
• Low-stress processing and decarboxylation-control strategy
• Packaging and stability-development planning
• Funding and non-dilutive financing assessment
• Preparation of the next formulation-development and preclinical stages

THCA PURE™ Oral remains an investigational development concept. Product manufacturability, stability, safety, bioavailability, and clinical efficacy have not yet been established.